Intercellular Adhesion Molecule 1 (ICAM-1) and Vascular Cell Adhesion Molecule 1 (VCAM-1) leukocyte adhesion pathways (ICAM-1/VCAM-1)

The ICAM-1/VCAM-1 leukocyte adhesion pathways are essential mechanisms for the recruitment of immune cells to sites of inflammation and injury [1, 2]. These pathways involve the interaction between cell adhesion molecules (CAMs) on the vascular endothelium and integrin receptors on the surface of circulating leukocytes [3, 10]. Intercellular Adhesion Molecule 1 (ICAM-1) and Vascular Cell Adhesion Molecule 1 (VCAM-1) are members of the immunoglobulin superfamily that are upregulated by pro-inflammatory cytokines like TNF-alpha and IL-1beta [2, 3]. ICAM-1 primarily binds to the beta-2 integrins LFA-1 and Mac-1, while VCAM-1 binds to the alpha-4 integrin VLA-4 [1, 10]. This binding facilitates the firm adhesion of leukocytes to the vessel wall, a prerequisite for their subsequent transmigration into the underlying tissue [1, 15]. Pathological overactivation of these pathways is a hallmark of various inflammatory and autoimmune disorders, such as multiple sclerosis, inflammatory bowel disease, and atherosclerosis [3, 8, 10]. Consequently, these pathways are major therapeutic targets, with drugs like natalizumab and lifitegrast designed to block these interactions and prevent excessive leukocyte infiltration [4, 15]. However, therapeutic modulation of these pathways carries risks, including increased susceptibility to infections due to impaired immune surveillance [4, 11].

Other names

CD54CD106Intercellular Adhesion Molecule 1Vascular Cell Adhesion Molecule 1Leukocyte adhesion cascadeEndothelial-leukocyte adhesion pathwayINCAM-100

Inhibition of leukocyte-endothelial adhesion and transmigration by blocking the interaction between endothelial adhesion molecules (ICAM-1, VCAM-1) and their leukocyte integrin receptors (LFA-1, VLA-4).